Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04999020 · ClinicalTrials.gov registry record · Phase 2
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT04999020 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT04999020, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).
Interventions
- DRUG Placebo
- DRUG Ravulizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2024-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04999020
The ClinicalTrials.gov registry entry for NCT04999020 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04999020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04999020 about?
NCT04999020 is a clinical study titled "Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis". This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).
What is the current status of trial NCT04999020?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2021-11-19. Estimated completion is 2024-05-08.
What interventions are being tested in trial NCT04999020?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT04999020?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.